Astellas said it has removed a Phase 1 cancer asset as well as a small molecule that came from its Mitobridge acquisition.
PITTSBURGH and CAMBRIDGE, Mass., Feb. 8, 2023 /PRNewswire/ -- Generian Pharmaceuticals, Inc., a preclinical biopharmaceutical company discovering and developing first-in-class orally bioavailable small molecule therapeutics, announced today that it has achieved the first research milestones for two programs in development under its collaboration agreement with Mitobridge, Inc. (a wholly-owned subsidiary of Astellas Pharma Inc.).